Hormonal therapy for breast cancer: An update

Hematology/Oncology Clinics of North America

Volumn 13, Issue 2, 1999, Pages 435-455

  Gradishar, W J ^a   Jordan, V C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FARNESDON; FORMESTANE; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; MEGESTROL ACETATE; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE; TAMOXIFEN DERIVATIVE; TOREMIFENE; UNCLASSIFIED DRUG; VOROZOLE;

BREAST CANCER; CANCER STAGING; DRUG EFFICACY; DRUG MECHANISM; HORMONAL THERAPY; HORMONE RESPONSE; ISCHEMIC HEART DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0032985589     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70064-2     Document Type: Article

References (108)

1. V.J. Assikis V.C. Jordan Tamoxifen and endometrial cancer: From experiment to patient Recent Results Cancer Res 140 1996 61 71
2. E. Bajetta N. Zilembo R. Buzzoni Goserelin in premenopausal advanced breast cancer: Clinical and endocrine evaluation of responsive patients Oncology 51 1994 262 269
3. G. Beatson On the treatment of inoperable cases of carcinoma of the mammary: Suggestions for a new method of treatment, with illustrative cases Lancet 2 1896 104 107 162–165
4. G. Beatson The treatment of cancer of the breast by oophorectomy and hyroid extract BMJ 2 1901 1145 1148
5. R.W. Blamey W. Jonat M. Kaufmann Goserelin depot in the treatment of premenopausal advanced breast cancer Eur J Cancer 1992 810 814
6. G. Block Estrogen excretion following operative and irradiation castration in cases of mammary cancer Surgery 43 1958 415 422
7. S. Boyd An oophorectomy in cancer of the breast BMJ 2 1900 1161 1167
8. C. Brambilla A. Escobedo R. Artioli Treatment of pre-menopausal advanced breast cancer with goserelin—A long-acting luteinizing hormone releasing hormone agonist Anticancer Drugs 3 1992 3 8
9. R.B. Buchanan R.W. Blamey K.R. Durrant A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer J Clin Oncol 4 1986 1326 1330
10. A.U. Buzdar W. Jonat A. Howell Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group Cancer 83 1998 1142 1152
11. A.U. Buzdar R. Smith C. Vogel Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials Cancer 77 1996 2503 2513
12. P. Cech J.B. Block L.A. Cone Tumor lysis syndrome after tamoxifen flare [letter] N Engl J Med 315 1986 263 264
13. A. Clarysse Hormone-induced tumor flare [editorial] Eur J Cancer Clin Oncol 21 1985 545 547
14. R.C. Coombes S.W. Hughes M. Dowsett 4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer Eur J Cancer 12 1992 1941 1945
15. S. Cummings L. Norton S. Eckert Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 2a
16. D. Cunningham T.J. Powles M. Dowsett Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer Cancer Chemother Pharmacol 20 1987 253 255
17. F. DeCourmellers La radiotherapie indirecte, ou dirigee par les correlations organiques Archives d'Electricite Medicale 32 1922 264
18. L.M. Demers A. Lipton H.A. Harvey The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer J Steroid Biochem Mol Biol 44 1993 683 685
19. A.R. Dixon J.F. Robertson L. Jackson Goserelin (Zoladex) in premenopausal advanced breast cancer: Duration of response and survival Br J Cancer 62 1990 868 870
20. A.M. Dlugi J.D. Miller J. Knittle Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study. Lupron Study Group Fertil Steril 54 1990 419 427
21. P. Dombernowsky I. Smith G. Falkson Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 1998 453 461
22. M. Dowsett Aromatase inhibition: Basic concepts, and the pharmacodynamics of formestane Ann Oncol 5 1994 S3 S5
23. M. Dowsett R.C. Coombes Second generation aromatase inhibitor–4-hydroxyandrostenedione Breast Cancer Res Treat 30 1994 81 87
24. M. Dowsett D.C. Cunningham R.C. Stein Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients Cancer Res 49 1989 1306 1312
25. M. Dowsett A. Jones S.R.D. Johnston In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer Clinical Cancer Research 1 1995 1511 1515
26. M. Dowsett P.E. Lonning Anastrozole—A new generation in aromatase inhibition: Clinical pharmacology Oncology 54 1997 11 14
27. M. Dowsett D. Smithers J. Moore Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer Eur J Cancer 10 1994 1453 1458
28. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: An overview of the randomised trials Lancet 352 1998 930 942
29. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1998 1451 1467
30. M.J. Ellis D.F. Hayes Improving hormonal therapy for breast cancer Breast 3 suppl 1997 57 68
31. M. Filicori C. Flamigni GnRH agonists and antagonists. Current clinical status Drugs 35 1988 63 82
32. B. Fisher Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients J Clin Oncol 14 1996 1027 1039
33. B. Fisher J.P. Costantino C.K. Redmond Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 1994 527 537
34. B. Fisher J.P. Costantino D.L. Wickerham Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
35. M.H. Gail L.A. Brinton D.P. Byar Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1989 1879 1886
36. K.E. Gale J.W. Andersen D.C. Tormey Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen Cancer 73 1994 354 361
37. J. Geisler N. King G. Anker In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients Clinical Cancer Research 4 1998 2089 2093
38. J. Geisler N. King M. Dowsett Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer Br J Cancer 74 1996 1286 1291
39. M. Gershanovich H.A. Chaudri D. Campos Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3) Ann Oncol 9 1998 639 645
40. A. Goldhirsch J.H. Glick R.D. Gelber Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer J Natl Cancer Inst 90 1998 1601 1608
41. P.E. Goss Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor Breast Cancer Res Treat 49 1988 S59 S65 discussion S73–77
42. W.J. Gradishar V.C. Jordan Endocrine therapy of breast cancer K.I. Bland E.M. Copeland The Breast: Comprehensive Management of Benign and Malignant Disease ed 2 1998 WB Saunders Philadelphia 1350 1372
43. E.S. Greenwald Megestrol acetate flare [letter] Cancer Treatment Reports 67 1983 405
44. D.F. Hayes J.A. Van Zyl A. Hacking Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer J Clin Oncol 13 1995 2556 2566
45. G.N. Hortobagyi A.U. Buzdar Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: Mechanism of action and role in management Cancer Invest 16 1998 385 390
46. C. Huggins D. Bergenstal Inhibition of human mammary and prostatic cancer by adrenalectomy Cancer Res 12 1952 134 141
47. C. Huggins T. Dao Adrenalectomy and oophorectomy in the treatment of advanced carcinoma of the breast JAMA 151 1953 1388 1394
48. C. Huggins C. Hodges Studies on prostatic cancer. Effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
49. J.N. Ingle P.A. Johnson V.J. Suman A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma Cancer 80 1997 218 224
50. J.N. Ingle J.E. Krook S.J. Green Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer J Clin Oncol 4 1986 178 185
51. T.J. Iveson J. Ahern I.E. Smith Response to third-line endocrine treatment for advanced breast cancer Eur J Cancer 4 1993 572 574
52. I.A. Jaiyesimi A.U. Buzdar D.A. Decker Use of tamoxifen for breast cancer: Twenty-eight years later J Clin Oncol 13 1995 513 529
53. W. Jonat Clinical overview of anastrozole—A new selective oral aromatase inhibitor Oncology 54 1997 15 18
54. S.E. Jones A.Y.C. Chang C.J. Lusch Antitumor efficacy of Aromasin (exemestane) in postmenopausal women with metastatic breast cancer failing tamoxifen and Megace Breast Cancer Res Treat 50 1998 290
55. V. Jordan J. Glusman S. Eckert Raloxifene reduces incident breast cancers. Integrated data from multi-center, double-blind, placebo-controlled randomized trials in postmenopausal women Breast Cancer Res Treat 50 1998 227
56. V.C. Jordan V.J. Assikis Endometrial carcinoma and tamoxifen: Clearing up a controversy Clinical Cancer Research 1 1995 467 472
57. V.C. Jordan W.J. Gradishar Molecular mechanisms and future uses of antiestrogens Mol Aspects Med 18 1997 167 247
58. S. Karlsson M.J. Iatropoulos G.M. Williams The proliferation in uterine compartments of intact rats of two different strains exposed to high doses of tamoxifen or toremifene Toxicol Pathol 26 1998 759 768
59. M. Kaufmann W. Jonat E. Schachner-Wunschmann The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer—A 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group Onkologie 14 1991 22 24 26–28, 30
60. T. Kuukasjarvi J. Kononen H. Helin Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 1996 2584 2589
61. S.H. Landis T. Murray S. Bolden Cancer statistics, 1998 CA Cancer J Clin 48 1998 6 29
62. P.E. Lonning E. Bajetta R. Murray A phase II study of exemestane in metastatic breast cancer patients failing non-steroidal aromatase inhibitors Breast Cancer Res Treat 50 1998 304
63. E.G. Lufkin M.D. Whitaker T. Nickelsen Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial J Bone Miner Res 13 1998 1747 1754
64. S. Lundgren S. Gundersen R. Klepp Megestrol acetate versus aminoglutethimide for metastatic breast cancer Breast Cancer Res Treat 14 1989 201 206
65. W.L. McGuire G.C. Chamness S.A. Fuqua Estrogen receptor variants in clinical breast cancer Mol Endocrinol 5 1991 1571 1577
66. W.L. McGuire P.A. Johnson H.B. Muss Megestrol acetate in breast cancer—A panel discussion Breast Cancer Res Treat 14 1989 33 38
67. A.A. Miller R. Becher C.G. Schmidt Plasma concentrations of medroxyprogesterone acetate and megestrol acetate during long-term follow-up in patients treated for metastatic breast cancer J Cancer Res Clin Oncol 114 1988 186 190
68. W.R. Miller Aromatase inhibitors and breast cancer Cancer Treat Rev 23 1997 171 187
69. W.R. Miller Aromatase inhibitors in the treatment of advanced breast cancer Cancer Treat Rev 16 1989 83 93
70. W.R. Miller Endocrine treatment for breast cancers: Biological rationale and current progress J Steroid Biochem Mol Biol 37 1990 467 480
71. W.R. Miller Fundamental research leading to improved endocrine therapy for breast cancer J Steroid Biochem Mol Biol 27 1987 477 485
72. W.R. Miller P. Mullen P. Sourdaine Regulation of aromatase activity within the breast J Steroid Biochem Mol Biol 61 1997 193 202
73. W.R. Miller P. Mullen J. Telford Clinical importance of intratumoral aromatase Breast Cancer Res Treat 49 1998 S27 S32 discussion S33–37
74. H.B. Muss L.D. Case R.L. Capizzi High- versus standard-dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association J Clin Oncol 8 1990 1797 1805
75. H.B. Muss E.H. Paschold W.R. Black Megestrol acetate v tamoxifen in advanced breast cancer: A phase III trial of the Piedmont Oncology Association (POA) Semin Oncol 12 1985 55 61
76. R.M. O'Regan A. Cisneros G.M. England Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth J Natl Cancer Inst 90 1998 1552 1558
77. C.K. Osborne Tamoxifen in the treatment of breast cancer N Engl J Med 339 1998 1609 1618
78. L.A. Otteman H.J. Long Hypercalcemic flare with megestrol acetate [letter] Cancer Treatment Reports 68 1984 1420 1421
79. R. Perez-Carrion V. Alberola-Candel F. Calabresi Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer Ann Oncol 5 1994 S19 S24
80. R. Peto Five years of tamoxifen–or more? J Natl Cancer Inst 88 1996 1791 1793
81. T. Pickles L. Perry P. Murray 4-Hydroxyandrostenedione—Further clinical and extended endocrine observations Br J Cancer 62 1990 309 313
82. D. Plotkin J.J. Lechner W.E. Jung Tamoxifen flare in advanced breast cancer JAMA 240 1978 2644 2646
83. P. Pronzato F. Brema D. Amoroso Megestrol acetate: Phase II study of a single daily administration in advanced breast cancer Breast Cancer Res Treat 17 1990 51 54
84. J.S. Richards G.J. Hickey S.A. Chen Hormonal regulation of estradiol biosynthesis, aromatase activity, and aromatase mRNA in rat ovarian follicles and corpora lutea Steroids 50 1987 393 409
85. C. Rose H. Mouridsen Preferred sequence of endocrine therapies in advanced breast cancer R. Santen E. Juhos Endocrine-Dependent Breast Cancer: Critical Assessment of Recent Advances 1988 Hans Huber Publishers Bern 81
86. M. Rozencweig J. Heuson Breast Cancer: Prognostic Factors and Clinical Evaluation 1975 Raven Press New York
87. E. Samojlik J.D. Veldhuis S.A. Wells Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma J Clin Invest 65 1980 602 612
88. R.J. Santen Clinical use of aromatase inhibitors: Current data and future perspectives J Enzym Inhib 4 1990 79 99
89. R.J. Santen A. Manni H. Harvey Endocrine treatment of breast cancer in women Endocr Rev 11 1990 221 265
90. R.J. Santen R.I. Misbin Aminoglutethimide: Review of pharmacology and clinical use Pharmacotherapy 1 1981 95 120
91. R.J. Santen E. Samojlik S.A. Wells Resistance of the ovary to blockade of aromatization with aminoglutethimide J Clin Endocrinol Metab 51 1980 473 477
92. R.J. Santen T.J. Worgul E. Samojlik A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer N Engl J Med 305 1981 545 551
93. S.M. Sedlacek An overview of megestrol acetate for the treatment of advanced breast cancer Semin Oncol 15 1988 3 13
94. E.R. Simpson J.C. Merrill A.J. Hollub Regulation of estrogen biosynthesis by human adipose cells Endocr Rev 10 1989 136 148
95. P.E. Sipila V.J. Wiebe G.B. Hubbard Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo Eur J Cancer 15 1993 2138 2144
96. V. Spataro A. Goldhirsch Breast cancer: Relevance of estrogen receptor determination at relapse J Clin Oncol 15 1997 862
97. V. Spataro K. Price A. Goldhirsch Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group Ann Oncol 3 1992 733 740
98. B. Thurlimann R. Paridaens D. Serin Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study. Exemestane Study Group Eur J Cancer 33 1997 1767 1773
99. E. Tomas A. Kauppila G. Blanco Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients Gynecol Oncol 59 1995 261 266
100. E. van der Wall T.H. Donker E. de Frankrijker Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women Cancer Res 53 1993 4563 4566
101. C.L. Vogel Phase II and III clinical trials of toremifene for metastatic breast cancer Oncology (Huntingt) 12 1998 9 13
102. C.L. Vogel J. Schoenfelder I. Shemano Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer J Clin Oncol 13 1995 1123 1128
103. C.L. Vogel I. Shemano J. Schoenfelder Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer J Clin Oncol 11 1993 345 350
104. C.P. West D.T. Baird Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue Clin Endocrinol (Oxf) 26 1987 213 220
105. V.J. Wiebe C.K. Osborne S.A. Fuqua Tamoxifen resistance in breast cancer Crit Rev Oncol Hematol 14 1993 173 188
106. S.L. Willhite S.R. Goebel J.A. Scoggin Raloxifene provides an alternative for osteoporosis prevention Ann Pharmacother 32 1998 834 837
107. A. Wilson Response in breast cancer to a second-line therapy Review of Endocrine-Related Cancer 14 1983 5 11
108. J. Witliff Steroid-hormone receptors in breast cancer Cancer 53 1984 630 643